To invest in stocks, look at the research reports of Golden Kylin analysts, authoritative, professional, timely and comprehensive, helping you tap potential themed opportunities!
Original title: A piece of news from the World Health Organization made China’s richest man Zhong Suisui’s net worth drop by 10 billion
The World Health Organization (WHO) announced on its official website that it held a meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) from April 4 to 7 to review the evidence for single-dose human papillomavirus (HPV) vaccination. The review concluded that a single-dose HPV vaccination regimen was effective in preventing cervical cancer caused by persistent HPV infection and was comparable to a two-dose or three-dose regimen.
Articles produced by Radar Finance | Edited by Zhang Kaijing | Deep Sea
On April 14, the World Health Organization (WHO) announced on its official website that it held a meeting of the Strategic Advisory Group of Experts on Immunization (SAGE) from April 4 to 7 to discuss a single-dose human papillomavirus (HPV) vaccine. Evidence for vaccination was reviewed and it was concluded that a single-dose HPV vaccination regimen was effective in preventing cervical cancer caused by persistent HPV infection and was comparable to a two- or three-dose regimen.
“Seriously? Then why should I spend more than 2,000 for the last two injections?” Some netizens sighed.
Affected by this news, domestic HPV related companiesZhifei Biological、Wantai Bio、Watson BioThe stock prices all fell to varying degrees, among which Zhifei Bio fell more than 14%, Wantai Bio fell more than 9%, and Watson Bio fell more than 3%. The market value of the three companies has dropped by nearly 50 billion yuan.
Radar Finance noticed that not long ago, Zhong Suisui, the actual controller behind Wantai Bio, just reached the top of the Hurun Global Rich List for the second consecutive year as the richest man in China.straight flushiFind shows that Zhong Suisui holds a total of over 74% of Wantai Bio through his personal and Yangshengtang company. Based on this calculation, Zhong Suisui’s net worth dropped by about 12 billion yuan in one day.
Why did this news from the World Health Organization have such a big chain reaction?
It is understood that HPV is the main cause of cervical cancer, and vaccination is one of the most effective ways to prevent HPV infection. In this context, cervical cancer has become the only vaccine-preventable disease. cancer.
In November 2020, WHO launched the “Global Strategy to Accelerate the Elimination of Cervical Cancer”, which received positive responses from 194 countries, including my country. Since then, the process of HPV vaccination in my country has accelerated.
According to the different types of HPV prevention, the mainstream vaccines currently on the market are divided into bivalent, quadrivalent and 9-valent. Among them, the domestic four-price and nine-price are monopolized by Merck & Co. of the United States, and the second-price has three options: British GlaxoSmithKline, my country’s Wantai Bio, and Watson Bio.
Zhifei Bio is Merck’s domestic agent. In 2021, the company’s revenue from the agent of Merck’s HPV vaccine alone will exceed 30 billion yuan.
It is worth noting that Wantai Bio’s domestic bivalent HPV vaccine was not approved for marketing until 2019, while Watson Bio’s bivalent HPV vaccine was approved for marketing on March 24, 2022. Before breaking the monopoly of foreign companies, vaccinators need to get 3 shots regardless of the price of the vaccine. Under normal circumstances, the prices are 1,300 yuan/injection at nine prices, 800 yuan/injection at four prices, and 600 yuan/injection at two prices.
On the other hand, Wantai Bio and Watson Bio have reduced the number of doses for 9-14-year-old vaccinated people to 2 doses, and the price of each dose has been almost halved compared to before.
However, this is only ideal. Due to the huge potential vaccinated population and very limited production capacity, the HPV vaccine has always been in short supply in the global market.
According to the 2021 “Health Times” citing data from the National Bureau of Statistics, the number of 20-45-year-old women alone will reach 292 million. In addition, according to the 2021 batch issuance data of the Central Inspection Institute, the batch issuance of Wantai Bio’s bivalent HPV vaccine in 2021 will exceed 10 million; 5.07 million 9-valent vaccines were issued in batches.
Roughly calculated, the gap between the supply and demand of HPV vaccines in the Chinese market is hundreds of millions.
The huge contradiction between supply and demand not only makes it difficult to obtain HPV vaccination qualifications, but also increases the cost of vaccination for vaccinators. Radar Finance searched Alipay for HPV nine-valent vaccine appointment and found that the appointment price displayed was mostly around 6,000 yuan.
A netizen who has been concerned about HPV vaccination for a long time said that it is difficult to make appointments in public hospitals now, and many people go to private hospitals for vaccinating. This price is normal.
In this case, the new WHO recommendations will undoubtedly greatly reduce the profits of HPV vaccine-related companies.
It is understood that part of the meeting minutes on HPV vaccine takes into account the coverage of HPV vaccine, the goal of eliminating cervical cancer by 2030, and the impact of the current new crown epidemic on vaccination. SAGE recommends the following immunization procedures: 9-14-year-old female Priority groups) 1 or 2 doses; 1 or 2 doses for women aged 15-20; 2 doses for women over 21 (6 months apart).
In response, Wantai Bio announced in response that it has paid attention to the public information on the World Health Organization website. The company’s currently approved bivalent HPV vaccine in China is 3 doses (2 doses for women aged 9-14). Under the current national drug administration policy, such as changes in vaccination doses, a series of clinical, data support and registration change procedures need to be performed, which will take a certain amount of time and will not have a significant impact on the company’s operating performance in the short term.
At the same time, Wantai Bio also stated that it is not ruled out that the WHO and the domestic government will actively promote the 1-dose or 2-dose vaccination program in the future. If existing manufacturers and new entrants are approved for registration through clinical trials and registration changes, and promote 1-dose or 2-dose immunization procedures at home or abroad, it will have a greater impact on the market supply and immunization of the entire cervical cancer vaccine. big impact.
And Zhifei Bio responded, “The vaccination program of the vaccine should be based on strict scientific demonstration. Merck’s quadrivalent and nine-valent HPV vaccines have accumulated a large number of clinical trials in terms of protective efficacy, protective effect, safety and durability of protective effect. and real-world data, and was approved by the State Drug Administration of China in 2017 and 2018. The current immunization program of the quadrivalent and nine-valent HPV vaccines marketed in China is three doses, and the program is based on clinical research in China Data-approved indications. We recommend that healthcare professionals and consumers follow regulatory-approved HPV vaccine labeling.”
If WHO’s recommendations are really implemented, what changes will it bring to the global HPV vaccine market landscape? Radar Finance will continue to pay attention.
Massive information, accurate interpretation, all in Sina Finance APP
Responsible editor: Zhang Yi